The Research Center for Clinical Neuroimmunology and Neuroscience Basel is an interdisciplinary research institution supported by a non-profit foundation.
Basel
Joined February 2022
- Tweets123
- Following79
- Followers143
- Likes217
RC2NB retweeted
Yes👍 from @SofiaSandgren1 @JensKuhle @RC2NB @UniBasel: Blood NfL can provide information on disease activity, prognosis and treatment response, both in drug development trials and in personalised medicine in #MultipleSclerosis.
🔽
journals.sagepub.com/doi/abs…
2/🧵
RC2NB retweeted
John Dystel Prize for Multiple Sclerosis Research awarded to Dr. Ludwig Kappos for his transformative contributions to MS research
eurekalert.org/news-releases…
RC2NB retweeted
In #MultipleSclerosis, treatment effects on blood neurofilament light chain #NfL are moderately associated with therapeutic effects on relapses and MRI lesions.
A meta-regression of randomized controlled trials from @RC2NB @UniBasel_en @unige_en ▶️ journals.sagepub.com/doi/abs…
RC2NB retweeted
OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in the care of people with #MultipleSclerosis.
🔓MSJ-ETC study from @Unispital_USZ @RC2NB ▶️ journals.sagepub.com/doi/ful…
RC2NB retweeted
Deep learning can automate the classification of paramagnetic rim and remyelinated lesions in #MultipleSclerosis, guiding personalized treatment decisions.
Study from @CristinaGranzi2 @RC2NB ▶️ journals.sagepub.com/doi/abs…
RC2NB retweeted
New study in Science Translational Medicine (@ScienceMagazine) from @akproebstel and colleagues reveals distinct immune signatures in MOG antibody–associated disease (MOGAD), distinguishing it from MS. Researchers from Zurich, Munich, Toulouse, Lyon, Bonn & Basel (@DepBiomedicine, @DKFBasel, @RC2NB) uncover key immune differences shaping future therapies.
👉🏻 Link: science.org/doi/10.1126/scit…
#MOGAD #MSResearch #Neuroinflammation
ALT Visual representation of neuroinflammation: red, reactive immune activity disrupting the normal blue neural network. The image symbolizes the immune dysregulation underlying MOG antibody–associated disease (MOGAD). Image Adobe Stock.
RC2NB retweeted
MSIF is proud to announce Professor Ludwig Kappos as the 2025 #CharcotAward recipient, honouring a lifetime of impact in #MSResearch. 🏆🔬
From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎
Read more: msintfederation.org/4ncra5K
@RC2NB
RC2NB retweeted
Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #MultipleSclerosis.
Machine learning study using EXPAND trial from @RC2NB @UniBasel_en @UniSpitalBasel ▶️ journals.sagepub.com/doi/ful…
RC2NB retweeted
Just 24 participants to go:
Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year.
Only possible through full embedding in routine care and with an outstanding team @RC2NB and #SMC and the wonderful support of our patients.
multiscript.rc2nb.ch/
RC2NB retweeted
Authors developed and validated SMARTCARE-EDSS training method to enable health care professionals to assess disability for decentralized trials in #MultipleSclerosis.
A Swiss multicenter, randomized, cross-over study from @UniSpitalBasel @RC2NB ▶️ journals.sagepub.com/doi/ful…
RC2NB retweeted
"[R]epair and damage processes within [#MultipleSclerosis] #lesions occur across the entire disease spectrum and their frequency correlates with patient disability, age, disease duration, and extent of neuroaxonal damage." doi.org/10.1002/ana.27102 @ThINk_Basel @RC2NB
RC2NB retweeted
A hearty congratulations to the following new ECTRIMS Executive Committee members: Prof Gabriel Bsteh from @MedUni_Wien, Prof @J_SastreGarriga from @cemcat_em, and Prof @ZippFrauke from @uni_mainz
More governance updates to follow! ➡️ bit.ly/3XWAmR7 #ECTRIMS2024
RC2NB retweeted
Great to see #MultiSCRIPT highlighted @ECTRIMS.
We @RC2NB hope this will be the future of real world evidence in MS.
Exciting news from the MultiSCRIPT Trial! We've hit 40% of our target with 373 participants. Welcome to Inselspital & Zurich University Hospital! Huge thanks to our dedicated team and participants. Learn more here: multiscript.rc2nb.ch/
RC2NB retweeted
Breaking new ground in personalized medicine: The #Clinnova project relies on decentralized #AI training to enable personalized therapies for autoimmune diseases while ensuring medical data protection. #FederatedLearning
@DKFBasel @UniSpitalBasel
unibas.ch/en/News-Events/New…
RC2NB retweeted
Biomarkers to Assess Multiple Sclerosis | MedPage Today medpagetoday.com/spotlight/a…
RC2NB retweeted
REFLEX study: Higher baseline #sNfL levels were associated with increased risk of conversion to #MultipleSclerosis, while treatment with sc #interferon β-1a delayed conversion time. doi.org/10.1177/175628642412…
@JensKuhle @RC2NB
RC2NB retweeted
New clue in MS brain protection: B cell therapy & a molecule called BAFF might work together to safeguard brain tissue. #MSresearch #Bcelltherapy #neuroprotection #MSresearch #BAFF (@proebstellab , Universities of Toronto, Mainz & Basel)
Link Publication: science.org/doi/10.1126/scit… @ScienceTM
RC2NB retweeted
There are 48 pragmatic trials 1967–2022 to assess mostly supportive care in #MultipleSclerosis (85%), with only 7 evaluating drugs (15%). New potential for randomized real-world evidence?
A systematic overview from @LGHemkens @RC2NB @UniBasel ▶️ journals.sagepub.com/doi/ful…
RC2NB retweeted
Central vein sign and cortical lesions may be valuable tools to increase the accuracy of multiple sclerosis diagnosis. ja.ma/3uWSw9d
RC2NB retweeted
Studien mit Patienten sind wertvoll für die Erforschung neuer Therapien – aber nur, wenn sie einem festgelegten Schema folgen. Doch deutsche Unis biegen sich dieses Schema häufig zurecht, wie eine Analyse aus #PlosMedicine zeigt. Mit @m_grill via @SZ sz.de/1.6302964
